Skip to main content
. 2010 May;69(5):484–497. doi: 10.1111/j.1365-2125.2010.03638.x

Table 5.

Population pharmacokinetic parameter estimates for total and unbound melphalan in 100 patients with multiple myeloma using separately developed Covariate Models that incorporated CLcr with units ml min−1 70 kg−1

Total melphalan Unbound melphalan
Parameter Mean Bootstrap mean (%diff, 95% CI) Mean Bootstrap mean (%diff, 95% CI)
Fixed effects
CLNR (l h−1)
θ1 17 17 (0%, 13.5–21.3) 79.7 80.3 (0.8%, 64.8, 97.3)
θ2 0.462 0.463 (0.2%, 0.060, 0.954) 0.679 0.682 (0.4%, 0.284, 1.070)
CLR (l h−1) 11.1 11.2 (0.9%, 6.8, 14.6) 50.7 49.8 (−1.8%, 34.8, 66.1)
V1 (l) 13.2 13.3 (0.8%, 11.0, 15.6) 63.8 65.0 (1.9%, 50.6, 78.1)
Q (l h−1) 30.6 30.5 (−0.3%, 26.5, 34.2) 152 146.5 (−3.6%, 123.0, 171.0)
V2 (l) 15 15 (0%, 13.8, 16.2) 71.6 70.3 (−1.8%, 62.7, 78.4)
Interindividual variability
ωCL (CV%) 26.7 26.7 (0%, 21.7, 31.8) 29.8 29.8 (0%, 23.0, 37.1)
ωV1 (CV%) 57.9 57.9 (0%, 38.0, 75.9) 38.7 39.8 (2.8%, 17.6, 65.6)
ωQ (CV%) 41.1 41.5 (1%, 27.3, 55.9) 49.6 46.3 (−6.7%, 26.9, 60.5)
ωV2 (CV%) 34.5 34.1 (−1.2%, 25.9, 42.9) 35.4 37.6 (6.2%, 26.8, 49.2)
Random residual variability
σ1 (SD) 0.072 0.072 (0%, 0.060, 0.083) 0.138 0.131 (−5.1%, 0.104, 0.155)
σ2 (SD) 0.082 0.081 (−1.2%, 0.060, 0.107) 0.027 0.028 (3.7%, 0.003, 0.051)
OBV −876 −1535
Structural models:
CL = CLNR+ CLR, where CLNR1× (HCT/34)θ2× (FFM/50)0.75 and CLR3× (CLcr/88), V1 =θ4× (FFM/50), Q =θ5, V2 =θ6

95% CI = lower and upper limits of the 95% confidence interval for population pharmacokinetic parameters obtained with 1000 bootstrap runs. %diff = (bootstrap mean – Covariate model mean)/Covariate model mean × 100, OBV = Objective function value. CL, clearance; CLcr, estimated creatinine clearance (ml min−1 70 kg−1); %CV, coefficient of variation; FFM, fat free mass (kg); HCT, haematocrit (%); Q, Intercompartmental clearance; SD, standard deviation; V1, Volume of distribution into the central compartment; V2, Volume of distribution into the peripheral compartment; WT, weight.